264 related articles for article (PubMed ID: 27888143)
1. Dissolution behavior of co-amorphous amino acid-indomethacin mixtures: The ability of amino acids to stabilize the supersaturated state of indomethacin.
Ojarinta R; Heikkinen AT; Sievänen E; Laitinen R
Eur J Pharm Biopharm; 2017 Mar; 112():85-95. PubMed ID: 27888143
[TBL] [Abstract][Full Text] [Related]
2. Preparation and characterization of spray-dried co-amorphous drug-amino acid salts.
Jensen KT; Blaabjerg LI; Lenz E; Bohr A; Grohganz H; Kleinebudde P; Rades T; Löbmann K
J Pharm Pharmacol; 2016 May; 68(5):615-24. PubMed ID: 26245703
[TBL] [Abstract][Full Text] [Related]
3. Spray drying of poorly soluble drugs from aqueous arginine solution.
Ojarinta R; Lerminiaux L; Laitinen R
Int J Pharm; 2017 Oct; 532(1):289-298. PubMed ID: 28890173
[TBL] [Abstract][Full Text] [Related]
4. Dissolution properties of co-amorphous drug-amino acid formulations in buffer and biorelevant media.
Heikkinen AT; DeClerck L; Löbmann K; Grohganz H; Rades T; Laitinen R
Pharmazie; 2015 Jul; 70(7):452-7. PubMed ID: 26373205
[TBL] [Abstract][Full Text] [Related]
5. Undesired co-amorphisation of indomethacin and arginine during combined storage at high humidity conditions.
Petry I; Löbmann K; Grohganz H; Rades T; Leopold CS
Int J Pharm; 2018 Jun; 544(1):172-180. PubMed ID: 29669257
[TBL] [Abstract][Full Text] [Related]
6. Amino acids as co-amorphous stabilizers for poorly water soluble drugs--Part 1: preparation, stability and dissolution enhancement.
Löbmann K; Grohganz H; Laitinen R; Strachan C; Rades T
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):873-81. PubMed ID: 23537574
[TBL] [Abstract][Full Text] [Related]
7. Supersaturation of zafirlukast in fasted and fed state intestinal media with and without precipitation inhibitors.
Madsen CM; Boyd B; Rades T; Müllertz A
Eur J Pharm Sci; 2016 Aug; 91():31-9. PubMed ID: 27260089
[TBL] [Abstract][Full Text] [Related]
8. Solid-state properties and dissolution behaviour of tablets containing co-amorphous indomethacin-arginine.
Lenz E; Jensen KT; Blaabjerg LI; Knop K; Grohganz H; Löbmann K; Rades T; Kleinebudde P
Eur J Pharm Biopharm; 2015 Oct; 96():44-52. PubMed ID: 26197392
[TBL] [Abstract][Full Text] [Related]
9. Preparation and characterization of multi-component tablets containing co-amorphous salts: Combining multimodal non-linear optical imaging with established analytical methods.
Ojarinta R; Saarinen J; Strachan CJ; Korhonen O; Laitinen R
Eur J Pharm Biopharm; 2018 Nov; 132():112-126. PubMed ID: 30248394
[TBL] [Abstract][Full Text] [Related]
10. Could the small molecules such as amino acids improve aqueous solubility and stabilize amorphous systems containing Griseofulvin?
França MT; Marcos TM; Pereira RN; Stulzer HK
Eur J Pharm Sci; 2020 Feb; 143():105178. PubMed ID: 31812717
[TBL] [Abstract][Full Text] [Related]
11. Preparation and characterization of co-amorphous Ritonavir-Indomethacin systems by solvent evaporation technique: improved dissolution behavior and physical stability without evidence of intermolecular interactions.
Dengale SJ; Ranjan OP; Hussen SS; Krishna BS; Musmade PB; Gautham Shenoy G; Bhat K
Eur J Pharm Sci; 2014 Oct; 62():57-64. PubMed ID: 24878386
[TBL] [Abstract][Full Text] [Related]
12. Performance comparison between crystalline and co-amorphous salts of indomethacin-lysine.
Kasten G; Nouri K; Grohganz H; Rades T; Löbmann K
Int J Pharm; 2017 Nov; 533(1):138-144. PubMed ID: 28947246
[TBL] [Abstract][Full Text] [Related]
13. Amino acids as co-amorphous excipients for tackling the poor aqueous solubility of valsartan.
Huang Y; Zhang Q; Wang JR; Lin KL; Mei X
Pharm Dev Technol; 2017 Feb; 22(1):69-76. PubMed ID: 27050301
[TBL] [Abstract][Full Text] [Related]
14. Amino acids as co-amorphous stabilizers for poorly water-soluble drugs--Part 2: molecular interactions.
Löbmann K; Laitinen R; Strachan C; Rades T; Grohganz H
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):882-8. PubMed ID: 23567485
[TBL] [Abstract][Full Text] [Related]
15. Indomethacin co-amorphous drug-drug systems with improved solubility, supersaturation, dissolution rate and physical stability.
Fael H; Demirel AL
Int J Pharm; 2021 May; 600():120448. PubMed ID: 33675920
[TBL] [Abstract][Full Text] [Related]
16. Hot Melt Extrusion and Spray Drying of Co-amorphous Indomethacin-Arginine With Polymers.
Lenz E; Löbmann K; Rades T; Knop K; Kleinebudde P
J Pharm Sci; 2017 Jan; 106(1):302-312. PubMed ID: 27817830
[TBL] [Abstract][Full Text] [Related]
17. Influence of variation in molar ratio on co-amorphous drug-amino acid systems.
Jensen KT; Larsen FH; Löbmann K; Rades T; Grohganz H
Eur J Pharm Biopharm; 2016 Oct; 107():32-9. PubMed ID: 27368747
[TBL] [Abstract][Full Text] [Related]
18. Coamorphous drug systems: enhanced physical stability and dissolution rate of indomethacin and naproxen.
Löbmann K; Laitinen R; Grohganz H; Gordon KC; Strachan C; Rades T
Mol Pharm; 2011 Oct; 8(5):1919-28. PubMed ID: 21815614
[TBL] [Abstract][Full Text] [Related]
19. Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats.
Nielsen LH; Gordon S; Holm R; Selen A; Rades T; Müllertz A
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):942-51. PubMed ID: 24075980
[TBL] [Abstract][Full Text] [Related]
20. Physical characterization and stability of amorphous indomethacin and ranitidine hydrochloride binary systems prepared by mechanical activation.
Chieng N; Aaltonen J; Saville D; Rades T
Eur J Pharm Biopharm; 2009 Jan; 71(1):47-54. PubMed ID: 18644443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
